The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COLUMN
COLUMN
-
2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
-
The Time Is Now for Medical Affairs
January 17, 2014
-
Blue Ocean Recruiting
December 20, 2013
-
Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
-
A World of Opportunity for the Brave
November 1, 2013
-
Does HR Have an Image Problem?
September 20, 2013
-
Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
-
Watch out for the Gorilla when Hiring Talent
July 19, 2013
-
Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
-
Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
-
An Insider’s Perspective on Hiring in Japan
April 26, 2013
-
Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
-
Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
-
Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
-
What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
-
Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
-
Leading from Afar
October 22, 2012
-
“Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…